getimage-48-768x274.png
Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
May 06, 2021 08:30 ET | Capricor Therapeutics
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the...
getimage-48-768x274.png
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
April 29, 2021 08:00 ET | Capricor Therapeutics
LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for...
getimage-48-768x274.png
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 11, 2021 16:01 ET | Capricor Therapeutics
Exosomes Platform Technology-Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes- Cell Therapy Program-In...
getimage-48-768x274.png
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
March 09, 2021 09:15 ET | Capricor Therapeutics
-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- -Functional Enzyme Expression and Real-Time Imaging of mRNA...
getimage-48-768x274.png
Capricor Therapeutics to Present Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Update on March 11
March 04, 2021 09:00 ET | Capricor Therapeutics
LOS ANGELES, March 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company focused on the development of first-in-class cell- and exosome-based therapeutics...
getimage-48-768x274.png
Capricor Therapeutics Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines
February 01, 2021 09:15 ET | Capricor Therapeutics
-Technology Licensed from Johns Hopkins University- -Patient Data Demonstrates Validity of Novel Imaging-Based Approach Furthering Capricor’s Platform Advancement- LOS ANGELES, Feb. 01,...
getimage-48-768x274.png
Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes
January 19, 2021 09:15 ET | Capricor Therapeutics
-Enhanced Signaling Pathways Show Increased Potency Through Expression of MicroRNAs- -Publication Further Supports Capricor’s Exosome Platform Advancement- LOS ANGELES, Jan. 19, 2021 (GLOBE...
getimage-48-768x274.png
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
January 12, 2021 09:05 ET | Capricor Therapeutics
—Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply— —The collaboration aims...
getimage-48-768x274.png
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients
December 29, 2020 09:15 ET | Capricor Therapeutics
LOS ANGELES, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
getimage-48-768x274.png
Capricor Therapeutics Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19
November 24, 2020 07:30 ET | Capricor Therapeutics
- Data Expected Second Quarter 2021 - - The INSPIRE Trial Is Designed to Assess the Ability of CAP-1002 to Modulate the Cytokine Storm Associated With Severe COVID-19 - LOS ANGELES, Nov. ...